Spots Global Cancer Trial Database for A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma
Official Title: A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma
Study ID: NCT02811822
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate GMI-1271, a specific E-selectin antagonist, in multiple myeloma as adjunct to standard of care chemotherapy used to treat this disease.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Vejle Hospital, Vejle, , Denmark
Medizinische Klinik/Abt. Innere Medizin V, Heidelberg, , Germany
Cork University Hospital, Wilton, Cork, , Ireland
Beaumont Hospital, Dublin, , Ireland
National University Ireland - Galway, Galway, , Ireland
Sheffield Teaching Hospital, Sheffield, England, United Kingdom
Saint James's University Hospital Leeds, Leeds, , United Kingdom
University College London Hospitals, London, , United Kingdom
Contact Details
Name: Michael O'Dwyer, MD
Affiliation: National University Ireland - Galway
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
